Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 24

    1.

    Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.

    Cyran CC, Paprottka PM, Schwarz B, Sourbron S, Ingrisch M, von Einem J, Pietsch H, Dietrich O, Hinkel R, Bruns CJ, Reiser MF, Wintersperger BJ, Nikolaou K.

    AJR Am J Roentgenol. 2012 Feb;198(2):384-91.

    PMID:
    22268182
    [PubMed - indexed for MEDLINE]
    2.

    Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.

    Bahl A, Bellmunt J, Oudard S.

    BJU Int. 2012 Mar;109 Suppl 2:14-9. doi: 10.1111/j.1464-410X.2011.10872.x.

    PMID:
    22257100
    [PubMed - indexed for MEDLINE]
    3.

    Sexual function with localized prostate cancer: active surveillance vs radical therapy.

    van den Bergh RC, Korfage IJ, Roobol MJ, Bangma CH, de Koning HJ, Steyerberg EW, Essink-Bot ML.

    BJU Int. 2012 Jan 19. doi: 10.1111/j.1464-410X.2011.10846.x. [Epub ahead of print]

    PMID:
    22260273
    [PubMed - as supplied by publisher]
    4.

    Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up.

    Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS.

    BMC Cancer. 2012 Jan 19;12:25.

    PMID:
    22260413
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.

    Taylor DJ, Parsons CE, Han H, Jayaraman A, Rege K.

    BMC Cancer. 2011 Nov 1;11:470.

    PMID:
    22044796
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.

    King MT, Viney R, Smith DP, Hossain I, Street D, Savage E, Fowler S, Berry MP, Stockler M, Cozzi P, Stricker P, Ward J, Armstrong BK.

    Br J Cancer. 2012 Feb 14;106(4):638-45. doi: 10.1038/bjc.2011.552. Epub 2012 Jan 24.

    PMID:
    22274410
    [PubMed - indexed for MEDLINE]
    7.

    Regulation of TGF-β1 expression by androgen deprivation therapy of prostate cancer.

    Fuzio P, Ditonno P, Rutigliano M, Battaglia M, Bettocchi C, Loverre A, Grandaliano G, Perlino E.

    Cancer Lett. 2012 May 28;318(2):135-44. doi: 10.1016/j.canlet.2011.08.034. Epub 2011 Oct 1.

    PMID:
    22269108
    [PubMed - indexed for MEDLINE]
    8.

    ARN-509: a novel antiandrogen for prostate cancer treatment.

    Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

    Cancer Res. 2012 Mar 15;72(6):1494-503. Epub 2012 Jan 20.

    PMID:
    22266222
    [PubMed - indexed for MEDLINE]
    9.

    Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1,6)-branched oligosaccharides as a marker of tumor progression.

    Lange T, Ullrich S, Müller I, Nentwich MF, Stübke K, Feldhaus S, Knies C, Hellwinkel OJ, Vessella RL, Abramjuk C, Anders M, Schröder-Schwarz J, Schlomm T, Huland H, Sauter G, Schumacher U.

    Clin Cancer Res. 2012 Mar 1;18(5):1364-73. Epub 2012 Jan 18.

    PMID:
    22261809
    [PubMed - in process]
    10.

    Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.

    Scher HI, Nasso SF, Rubin EH, Simon R.

    Clin Cancer Res. 2011 Nov 1;17(21):6634-40.

    PMID:
    22046024
    [PubMed - indexed for MEDLINE]
    11.

    The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.

    Wu GH, Auvinen A, Yen AM, Hakama M, Tammela TL, Stenman UH, Kujala P, Ruutu M, Chen HH.

    Eur Urol. 2012 May;61(5):1011-8. Epub 2012 Jan 14.

    PMID:
    22264679
    [PubMed - in process]
    12.

    A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.

    Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, Nelson CC; the Australian Prostate Cancer BioResource, Greenberg NM, Butler LM, Tilley WD.

    Int J Cancer. 2012 Aug 1;131(3):662-672. doi: 10.1002/ijc.26414. Epub 2012 Jan 24.

    PMID:
    22275114
    [PubMed - as supplied by publisher]
    13.

    Inhibition of androgen-responsive LNCaP prostate cancer cell tumor xenograft growth by dietary phenethyl isothiocyanate correlates with decreased angiogenesis and inhibition of cell attachment.

    Hudson TS, Perkins SN, Hursting SD, Young HA, Kim YS, Wang TC, Wang TT.

    Int J Oncol. 2012 Apr;40(4):1113-21. doi: 10.3892/ijo.2012.1335. Epub 2012 Jan 17.

    PMID:
    22266918
    [PubMed - in process]
    14.

    The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

    Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JL, Abrahamsson PA, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP.

    Int J Oncol. 2012 Jan;40(1):5-12. doi: 10.3892/ijo.2011.1212. Epub 2011 Sep 28. Review.

    PMID:
    21956088
    [PubMed - indexed for MEDLINE]
    15.

    Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterations of protein post-translational processing.

    Davalli P, Rizzi F, Caldara GF, Davoli S, Corti A, Silva A, Astancolle S, Vitale M, Bettuzzi S, Arcari M, Azzali G.

    Int J Oncol. 2011 Dec;39(6):1521-7. doi: 10.3892/ijo.2011.1136. Epub 2011 Jul 20.

    PMID:
    21935569
    [PubMed - indexed for MEDLINE]
    16.

    The Impact of Brachytherapy on Prostate Cancer-Specific Mortality for Definitive Radiation Therapy of High-Grade Prostate Cancer: A Population-Based Analysis.

    Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN.

    Int J Radiat Oncol Biol Phys. 2012 Jan 21. [Epub ahead of print]

    PMID:
    22270175
    [PubMed - as supplied by publisher]
    17.

    Postoperative Radiotherapy in Prostate Cancer: The Case of the Missing Target.

    Croke J, Malone S, Roustan Delatour N, Belanger E, Avruch L, Morash C, Kayser C, Underhill K, Spaans J.

    Int J Radiat Oncol Biol Phys. 2012 Jan 21. [Epub ahead of print]

    PMID:
    22270169
    [PubMed - as supplied by publisher]
    18.

    Effect of Statins and Anticoagulants on Prostate Cancer Aggressiveness.

    Alizadeh M, Sylvestre MP, Zilli T, Van Nguyen T, Guay JP, Bahary JP, Taussky D.

    Int J Radiat Oncol Biol Phys. 2012 Jan 21. [Epub ahead of print]

    PMID:
    22270166
    [PubMed - as supplied by publisher]
    19.

    Use of a combination of variables along with the PCA3 assay in better defining the "low risk" patient: a message from Pretoria to Kyoto.

    Adam A.

    Int J Urol. 2011 Oct;18(10):736; author reply 737. doi: 10.1111/j.1442-2042.2011.02827.x. Epub 2011 Aug 4. No abstract available.

    PMID:
    21815939
    [PubMed - indexed for MEDLINE]
    20.

    The effect of radiation on semen quality and fertility in men treated with brachytherapy for early stage prostate cancer.

    Singh DK, Hersey K, Perlis N, Crook J, Jarvi K, Fleshner N.

    J Urol. 2012 Mar;187(3):987-9. Epub 2012 Jan 20.

    PMID:
    22264453
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk